Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/TCRM.S142471 http://scihub22266oqcxt.onion/10.2147/TCRM.S142471 C5931200!5931200!29740210     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Clin+Risk+Manag 2018 ; 14 (ä): 757-78 Nephropedia Template TP {{tp|p=29740210|t=2018. Emerging treatment options for the management of pemphigus vulgaris |pdf=|usr=}}{{29740210}} gab.com Text Emerging treatment options for the management of pemphigus vulgaris JO: Ther Clin Risk Manag http://www.kidney.de/pget.php?&tw=1&pmid=29740210 #FOAvip Pemphigus vulgaris (PV) is a life-threatening disease belonging to the pemphigus group of autoimmune intra-epidermal bullous diseases of the skin and mucosae. The therapeutic management of PV remains challenging and, in some cases, conventional therapy is not adequate to induce clinical remission. The cornerstone of PV treatment remains systemic corticosteroids. Although very effective, long-term corticosteroid administration is characterized by substantial adverse effects. Corticosteroid-sparing adjuvant therapies have been employed in the treatment of PV, aiming to reduce the necessary cumulative dose of corticosteroids. Specifically, immunosuppressive agents such as azathioprine and mycophenolate mofetil are widely used in PV. More recently, high-dose intravenous immunoglobulins, immunoadsorption, and rituximab have been established as additional successful therapeutic options. This review covers both conventional and emerging therapies in PV. In addition, it sheds light on potential future treatment strategies for this disease. Twit Text FOAVip Emerging treatment options for the management of pemphigus vulgaris ????Ther Clin Risk Manag http://www.kidney.de/pget.php?&tw=1&pmid=29740210 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29740210 #FOAvip English Wikipedia <ref>{{Cite pmid|29740210}}</ref> Emerging treatment options for the management of pemphigus vulgaris #MMPMID29740210 Kridin K Ther Clin Risk Manag 2018[]; 14 (ä): 757-78 PMID29740210show ga Pemphigus vulgaris (PV) is a life-threatening disease belonging to the pemphigus group of autoimmune intra-epidermal bullous diseases of the skin and mucosae. The therapeutic management of PV remains challenging and, in some cases, conventional therapy is not adequate to induce clinical remission. The cornerstone of PV treatment remains systemic corticosteroids. Although very effective, long-term corticosteroid administration is characterized by substantial adverse effects. Corticosteroid-sparing adjuvant therapies have been employed in the treatment of PV, aiming to reduce the necessary cumulative dose of corticosteroids. Specifically, immunosuppressive agents such as azathioprine and mycophenolate mofetil are widely used in PV. More recently, high-dose intravenous immunoglobulins, immunoadsorption, and rituximab have been established as additional successful therapeutic options. This review covers both conventional and emerging therapies in PV. In addition, it sheds light on potential future treatment strategies for this disease. äEmerging treatment options for the management of pemphigus vulgaris (epmc).pdf DeepDyve Pubget Overpricing